NZ511922A - Homologous 28-kilodalton immunodominant protein genes of ehrlichia canis and uses thereof - Google Patents
Homologous 28-kilodalton immunodominant protein genes of ehrlichia canis and uses thereofInfo
- Publication number
- NZ511922A NZ511922A NZ511922A NZ51192299A NZ511922A NZ 511922 A NZ511922 A NZ 511922A NZ 511922 A NZ511922 A NZ 511922A NZ 51192299 A NZ51192299 A NZ 51192299A NZ 511922 A NZ511922 A NZ 511922A
- Authority
- NZ
- New Zealand
- Prior art keywords
- seq
- protein
- sequence
- canis
- dna
- Prior art date
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 195
- 241000605312 Ehrlichia canis Species 0.000 title claims abstract description 124
- 229940051998 ehrlichia canis Drugs 0.000 title claims abstract description 55
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 95
- 108091028043 Nucleic acid sequence Proteins 0.000 claims abstract description 37
- 206010020429 Human ehrlichiosis Diseases 0.000 claims abstract description 9
- 210000002966 serum Anatomy 0.000 claims abstract description 3
- 108020004414 DNA Proteins 0.000 claims description 60
- 238000000034 method Methods 0.000 claims description 29
- 150000007523 nucleic acids Chemical class 0.000 claims description 29
- 108010076504 Protein Sorting Signals Proteins 0.000 claims description 23
- 239000013598 vector Substances 0.000 claims description 21
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims description 18
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims description 18
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 16
- 108020004707 nucleic acids Proteins 0.000 claims description 14
- 102000039446 nucleic acids Human genes 0.000 claims description 14
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 14
- 239000000203 mixture Substances 0.000 claims description 13
- 229920001184 polypeptide Polymers 0.000 claims description 13
- 239000013604 expression vector Substances 0.000 claims description 12
- 241000282414 Homo sapiens Species 0.000 claims description 9
- 102000053602 DNA Human genes 0.000 claims description 7
- 101710127328 28 kDa antigen Proteins 0.000 claims description 5
- 230000002401 inhibitory effect Effects 0.000 claims description 5
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 5
- 208000024780 Urticaria Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000000427 antigen Substances 0.000 abstract description 13
- 108091007433 antigens Proteins 0.000 abstract description 13
- 102000036639 antigens Human genes 0.000 abstract description 13
- 150000001413 amino acids Chemical class 0.000 description 61
- 101710149506 28 kDa protein Proteins 0.000 description 58
- 101710137943 Complement control protein C3 Proteins 0.000 description 58
- 101710152003 Suppressor of silencing P0 Proteins 0.000 description 58
- 241000605310 Ehrlichia chaffeensis Species 0.000 description 49
- 210000004027 cell Anatomy 0.000 description 44
- 239000002773 nucleotide Substances 0.000 description 31
- 125000003729 nucleotide group Chemical group 0.000 description 30
- 241000282465 Canis Species 0.000 description 19
- 230000014509 gene expression Effects 0.000 description 19
- 108091026890 Coding region Proteins 0.000 description 18
- 239000012634 fragment Substances 0.000 description 17
- 239000000523 sample Substances 0.000 description 14
- 230000000890 antigenic effect Effects 0.000 description 13
- 108700026244 Open Reading Frames Proteins 0.000 description 12
- 238000004458 analytical method Methods 0.000 description 12
- 238000009396 hybridization Methods 0.000 description 12
- 241000282472 Canis lupus familiaris Species 0.000 description 11
- 101710113110 B-cell receptor-associated protein 31 Proteins 0.000 description 10
- 101710139711 IkB-like protein Proteins 0.000 description 10
- 101710081123 Interleukin-27 subunit alpha Proteins 0.000 description 10
- 230000000295 complement effect Effects 0.000 description 10
- 241000606675 Ehrlichia ruminantium Species 0.000 description 9
- 238000010367 cloning Methods 0.000 description 9
- 239000013612 plasmid Substances 0.000 description 9
- 238000012408 PCR amplification Methods 0.000 description 8
- 229940094937 thioredoxin Drugs 0.000 description 8
- 241000894006 Bacteria Species 0.000 description 7
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 7
- 239000008186 active pharmaceutical agent Substances 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 7
- 238000003776 cleavage reaction Methods 0.000 description 7
- 239000002299 complementary DNA Substances 0.000 description 7
- 108020004999 messenger RNA Proteins 0.000 description 7
- 238000010369 molecular cloning Methods 0.000 description 7
- 230000036961 partial effect Effects 0.000 description 7
- 108091008146 restriction endonucleases Proteins 0.000 description 7
- 230000007017 scission Effects 0.000 description 7
- 238000012163 sequencing technique Methods 0.000 description 7
- 238000013518 transcription Methods 0.000 description 7
- 230000035897 transcription Effects 0.000 description 7
- 241000605317 Anaplasmataceae Species 0.000 description 6
- 108091035707 Consensus sequence Proteins 0.000 description 6
- SHIBSTMRCDJXLN-UHFFFAOYSA-N Digoxigenin Natural products C1CC(C2C(C3(C)CCC(O)CC3CC2)CC2O)(O)C2(C)C1C1=CC(=O)OC1 SHIBSTMRCDJXLN-UHFFFAOYSA-N 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- 101150064138 MAP1 gene Proteins 0.000 description 6
- 101710138624 Otolith matrix protein 1 Proteins 0.000 description 6
- 108020004511 Recombinant DNA Proteins 0.000 description 6
- QONQRTHLHBTMGP-UHFFFAOYSA-N digitoxigenin Natural products CC12CCC(C3(CCC(O)CC3CC3)C)C3C11OC1CC2C1=CC(=O)OC1 QONQRTHLHBTMGP-UHFFFAOYSA-N 0.000 description 6
- SHIBSTMRCDJXLN-KCZCNTNESA-N digoxigenin Chemical compound C1([C@@H]2[C@@]3([C@@](CC2)(O)[C@H]2[C@@H]([C@@]4(C)CC[C@H](O)C[C@H]4CC2)C[C@H]3O)C)=CC(=O)OC1 SHIBSTMRCDJXLN-KCZCNTNESA-N 0.000 description 6
- 208000000292 ehrlichiosis Diseases 0.000 description 6
- 229940088598 enzyme Drugs 0.000 description 6
- 102000037865 fusion proteins Human genes 0.000 description 6
- 108020001507 fusion proteins Proteins 0.000 description 6
- 230000010076 replication Effects 0.000 description 6
- 150000003839 salts Chemical class 0.000 description 6
- 230000002103 transcriptional effect Effects 0.000 description 6
- 108010087118 Cowdria ruminantium major antigenic protein 1 Proteins 0.000 description 5
- 241000588724 Escherichia coli Species 0.000 description 5
- 101710159910 Movement protein Proteins 0.000 description 5
- 102000002933 Thioredoxin Human genes 0.000 description 5
- 230000003321 amplification Effects 0.000 description 5
- 230000027455 binding Effects 0.000 description 5
- 238000012512 characterization method Methods 0.000 description 5
- 230000029087 digestion Effects 0.000 description 5
- 230000028993 immune response Effects 0.000 description 5
- 238000003199 nucleic acid amplification method Methods 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 108060008226 thioredoxin Proteins 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 4
- 102100026061 Mannan-binding lectin serine protease 1 Human genes 0.000 description 4
- 101710161855 Methionine aminopeptidase 1 Proteins 0.000 description 4
- 101710103983 Modulator of apoptosis 1 Proteins 0.000 description 4
- 108091092724 Noncoding DNA Proteins 0.000 description 4
- 108091034117 Oligonucleotide Proteins 0.000 description 4
- 238000012300 Sequence Analysis Methods 0.000 description 4
- 238000002105 Southern blotting Methods 0.000 description 4
- 108091081024 Start codon Proteins 0.000 description 4
- 210000001744 T-lymphocyte Anatomy 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 230000001154 acute effect Effects 0.000 description 4
- 239000002671 adjuvant Substances 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 210000000349 chromosome Anatomy 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 238000005382 thermal cycling Methods 0.000 description 4
- 230000001131 transforming effect Effects 0.000 description 4
- 238000013519 translation Methods 0.000 description 4
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 3
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 3
- 108020004705 Codon Proteins 0.000 description 3
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 3
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 3
- 241000206602 Eukaryota Species 0.000 description 3
- 108700005084 Multigene Family Proteins 0.000 description 3
- 101710116435 Outer membrane protein Proteins 0.000 description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 230000002163 immunogen Effects 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 101150053109 p28 gene Proteins 0.000 description 3
- 230000002688 persistence Effects 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 230000002285 radioactive effect Effects 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 101710106459 29 kDa protein Proteins 0.000 description 2
- 229930024421 Adenine Natural products 0.000 description 2
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 241000605314 Ehrlichia Species 0.000 description 2
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 108091029795 Intergenic region Proteins 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 102000003992 Peroxidases Human genes 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 241001481696 Rhipicephalus sanguineus Species 0.000 description 2
- 230000024932 T cell mediated immunity Effects 0.000 description 2
- 108700009124 Transcription Initiation Site Proteins 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 229960000643 adenine Drugs 0.000 description 2
- 210000004102 animal cell Anatomy 0.000 description 2
- 208000022531 anorexia Diseases 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 150000001718 carbodiimides Chemical class 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 239000013599 cloning vector Substances 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 206010061428 decreased appetite Diseases 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 2
- -1 for example Chemical class 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 201000009162 human monocytic ehrlichiosis Diseases 0.000 description 2
- 230000028996 humoral immune response Effects 0.000 description 2
- 238000003119 immunoblot Methods 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 230000002480 immunoprotective effect Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- PHTQWCKDNZKARW-UHFFFAOYSA-N isoamylol Chemical compound CC(C)CCO PHTQWCKDNZKARW-UHFFFAOYSA-N 0.000 description 2
- 238000005304 joining Methods 0.000 description 2
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000007899 nucleic acid hybridization Methods 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- 235000020030 perry Nutrition 0.000 description 2
- 230000008488 polyadenylation Effects 0.000 description 2
- 230000004481 post-translational protein modification Effects 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 2
- 210000003705 ribosome Anatomy 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 206010043554 thrombocytopenia Diseases 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- 108010087967 type I signal peptidase Proteins 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 239000013603 viral vector Substances 0.000 description 2
- LLXVXPPXELIDGQ-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(2,5-dioxopyrrol-1-yl)benzoate Chemical compound C=1C=CC(N2C(C=CC2=O)=O)=CC=1C(=O)ON1C(=O)CCC1=O LLXVXPPXELIDGQ-UHFFFAOYSA-N 0.000 description 1
- QRXMUCSWCMTJGU-UHFFFAOYSA-L (5-bromo-4-chloro-1h-indol-3-yl) phosphate Chemical compound C1=C(Br)C(Cl)=C2C(OP([O-])(=O)[O-])=CNC2=C1 QRXMUCSWCMTJGU-UHFFFAOYSA-L 0.000 description 1
- 101150084750 1 gene Proteins 0.000 description 1
- 108020004465 16S ribosomal RNA Proteins 0.000 description 1
- 101150028074 2 gene Proteins 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 101710091601 21 kDa protein Proteins 0.000 description 1
- 101710170088 26 kDa periplasmic immunogenic protein Proteins 0.000 description 1
- 101150096316 5 gene Proteins 0.000 description 1
- QRXMUCSWCMTJGU-UHFFFAOYSA-N 5-bromo-4-chloro-3-indolyl phosphate Chemical compound C1=C(Br)C(Cl)=C2C(OP(O)(=O)O)=CNC2=C1 QRXMUCSWCMTJGU-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 241000606665 Anaplasma marginale Species 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 206010006895 Cachexia Diseases 0.000 description 1
- 101100024439 Caenorhabditis elegans msp-3 gene Proteins 0.000 description 1
- 101100516040 Caenorhabditis elegans nra-2 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282461 Canis lupus Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 102100038385 Coiled-coil domain-containing protein R3HCC1L Human genes 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- YVGGHNCTFXOJCH-UHFFFAOYSA-N DDT Chemical compound C1=CC(Cl)=CC=C1C(C(Cl)(Cl)Cl)C1=CC=C(Cl)C=C1 YVGGHNCTFXOJCH-UHFFFAOYSA-N 0.000 description 1
- 108020003215 DNA Probes Proteins 0.000 description 1
- 239000003298 DNA probe Substances 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- 102100029727 Enteropeptidase Human genes 0.000 description 1
- 108010013369 Enteropeptidase Proteins 0.000 description 1
- 241000672609 Escherichia coli BL21 Species 0.000 description 1
- 101100024440 Globodera rostochiensis MSP-3 gene Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010015776 Glucose oxidase Proteins 0.000 description 1
- 239000004366 Glucose oxidase Substances 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 206010020633 Hyperglobulinaemia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 241000235058 Komagataella pastoris Species 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- 208000008771 Lymphadenopathy Diseases 0.000 description 1
- 108010074338 Lymphokines Proteins 0.000 description 1
- 102000008072 Lymphokines Human genes 0.000 description 1
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 238000010222 PCR analysis Methods 0.000 description 1
- 206010033661 Pancytopenia Diseases 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- 101800001016 Picornain 3C-like protease Proteins 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 230000004570 RNA-binding Effects 0.000 description 1
- 101100173636 Rattus norvegicus Fhl2 gene Proteins 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 208000034712 Rickettsia Infections Diseases 0.000 description 1
- 208000033220 Rickettsial disease Diseases 0.000 description 1
- 241000606651 Rickettsiales Species 0.000 description 1
- 206010061495 Rickettsiosis Diseases 0.000 description 1
- 241000607715 Serratia marcescens Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- GYDJEQRTZSCIOI-UHFFFAOYSA-N Tranexamic acid Chemical compound NCC1CCC(C(O)=O)CC1 GYDJEQRTZSCIOI-UHFFFAOYSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 108010046334 Urease Proteins 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 238000003277 amino acid sequence analysis Methods 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000027645 antigenic variation Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- JPIYZTWMUGTEHX-UHFFFAOYSA-N auramine O free base Chemical compound C1=CC(N(C)C)=CC=C1C(=N)C1=CC=C(N(C)C)C=C1 JPIYZTWMUGTEHX-UHFFFAOYSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- HFACYLZERDEVSX-UHFFFAOYSA-N benzidine Chemical compound C1=CC(N)=CC=C1C1=CC=C(N)C=C1 HFACYLZERDEVSX-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000001268 conjugating effect Effects 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 125000005442 diisocyanate group Chemical group 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 208000026500 emaciation Diseases 0.000 description 1
- 230000006862 enzymatic digestion Effects 0.000 description 1
- 208000001780 epistaxis Diseases 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940116332 glucose oxidase Drugs 0.000 description 1
- 235000019420 glucose oxidase Nutrition 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 239000011544 gradient gel Substances 0.000 description 1
- 108010037896 heparin-binding hemagglutinin Proteins 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 235000011167 hydrochloric acid Nutrition 0.000 description 1
- 238000002169 hydrotherapy Methods 0.000 description 1
- 150000004679 hydroxides Chemical class 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 210000001822 immobilized cell Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000037451 immune surveillance Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- 150000002540 isothiocyanates Chemical class 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- DLBFLQKQABVKGT-UHFFFAOYSA-L lucifer yellow dye Chemical compound [Li+].[Li+].[O-]S(=O)(=O)C1=CC(C(N(C(=O)NN)C2=O)=O)=C3C2=CC(S([O-])(=O)=O)=CC3=C1N DLBFLQKQABVKGT-UHFFFAOYSA-L 0.000 description 1
- 208000018555 lymphatic system disease Diseases 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- MIKKOBKEXMRYFQ-WZTVWXICSA-N meglumine amidotrizoate Chemical compound C[NH2+]C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CC(=O)NC1=C(I)C(NC(C)=O)=C(I)C(C([O-])=O)=C1I MIKKOBKEXMRYFQ-WZTVWXICSA-N 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 238000007479 molecular analysis Methods 0.000 description 1
- 210000002864 mononuclear phagocyte Anatomy 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 230000000869 mutational effect Effects 0.000 description 1
- 210000004897 n-terminal region Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- JPXMTWWFLBLUCD-UHFFFAOYSA-N nitro blue tetrazolium(2+) Chemical compound COC1=CC(C=2C=C(OC)C(=CC=2)[N+]=2N(N=C(N=2)C=2C=CC=CC=2)C=2C=CC(=CC=2)[N+]([O-])=O)=CC=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=C([N+]([O-])=O)C=C1 JPXMTWWFLBLUCD-UHFFFAOYSA-N 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 238000002515 oligonucleotide synthesis Methods 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 150000003016 phosphoric acids Chemical class 0.000 description 1
- 238000013081 phylogenetic analysis Methods 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000001323 posttranslational effect Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 230000009465 prokaryotic expression Effects 0.000 description 1
- 230000004224 protection Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000007447 staining method Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000011426 transformation method Methods 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 125000002264 triphosphate group Chemical class [H]OP(=O)(O[H])OP(=O)(O[H])OP(=O)(O[H])O* 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 230000010415 tropism Effects 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 229940125575 vaccine candidate Drugs 0.000 description 1
- 108700026220 vif Genes Proteins 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/29—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Richettsiales (O)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/201,458 US6458942B1 (en) | 1998-11-30 | 1998-11-30 | 28-kDa immunoreactive protein gene of Ehrlichia canis and uses thereof |
| US09/261,358 US6403780B1 (en) | 1998-11-30 | 1999-03-03 | Homologous 28-kilodalton immunodominant protein genes of ehrlichia canis and uses thereof |
| PCT/US1999/028075 WO2000032745A2 (en) | 1998-11-30 | 1999-11-24 | Homologous 28-kilodalton immunodominant protein genes of ehrlichia canis and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ511922A true NZ511922A (en) | 2003-10-31 |
Family
ID=26896771
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ511922A NZ511922A (en) | 1998-11-30 | 1999-11-24 | Homologous 28-kilodalton immunodominant protein genes of ehrlichia canis and uses thereof |
Country Status (11)
| Country | Link |
|---|---|
| EP (1) | EP1470223A4 (https=) |
| JP (1) | JP2003527073A (https=) |
| CN (1) | CN1535314A (https=) |
| AU (1) | AU762315B2 (https=) |
| BR (1) | BR9916141A (https=) |
| CA (1) | CA2352466A1 (https=) |
| IL (1) | IL143415A0 (https=) |
| NZ (1) | NZ511922A (https=) |
| RU (1) | RU2237716C2 (https=) |
| TW (1) | TWI221481B (https=) |
| WO (1) | WO2000032745A2 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7888491B2 (en) | 1998-09-18 | 2011-02-15 | The Ohio State University Research Foundation | Outer membrane protein of Ehrlichia canis and Ehrlichia chaffeensis |
| US6544517B1 (en) | 1998-09-18 | 2003-04-08 | The Ohio State University Research Foundation | Outer membrane protein of Ehrlichia canis and Ehrlichia chaffeensis |
| US6392023B1 (en) | 1999-03-03 | 2002-05-21 | Research Development Foundation | Homologous 28-kilodalton immunodominant protein genes of Ehrlicha canis and uses thereof |
| US7335754B2 (en) | 1999-07-21 | 2008-02-26 | Cornell Research Foundation, Inc. | Ehrlichia canis genes and vaccines |
| US20020064531A1 (en) | 2000-05-01 | 2002-05-30 | Walker David H. | Ehrlichia chaffeensis 28 kDa outer membrane protein multigene family |
| US6432649B1 (en) * | 2000-08-25 | 2002-08-13 | The Ohio State University Research Foundation | Methods for detecting Ehrlichia canis and Ehrlichia chaffeensis in vertebrate and invertebrate hosts |
| WO2008137881A2 (en) | 2007-05-04 | 2008-11-13 | The Ohio State University Research Foundation | Ehrlichia ewingii proteins, nucleic acids, and methods of their use |
| WO2012135701A2 (en) | 2011-03-31 | 2012-10-04 | The Ohio State University | Compositions and methods for the detection of anaplasma platys |
| CN105051541B (zh) | 2012-10-11 | 2017-07-04 | 爱贝斯股份有限公司 | 用于检测埃里希体属抗体的肽、装置和方法 |
| US9442112B2 (en) * | 2014-04-04 | 2016-09-13 | Abaxis, Inc. | Compositions and methods for identifying Ehrlichia species |
| WO2025118050A1 (pt) * | 2023-12-04 | 2025-06-12 | Laboratório Bio-Vet Ltda | Antígeno vacinal quimérico com ação tríplice contra erliquiose, anaplasmose e babesiose canina, vetor de expressão, célula recombinante, composição vacinal, kit de diagnóstico, método de tratamento e uso de proteína quimérica |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6025338A (en) * | 1996-10-17 | 2000-02-15 | University Of Florida | Nucleic acid vaccines against rickettsial diseases and methods of use |
| CA2304256C (en) | 1997-09-19 | 2014-12-09 | Yasuko Rikihisa | Outer membrane protein of ehrlichia canis and ehrlichia chaffeensis |
-
1999
- 1999-11-24 JP JP2000585376A patent/JP2003527073A/ja not_active Withdrawn
- 1999-11-24 BR BR9916141-9A patent/BR9916141A/pt not_active Application Discontinuation
- 1999-11-24 RU RU2001117860A patent/RU2237716C2/ru active
- 1999-11-24 IL IL14341599A patent/IL143415A0/xx unknown
- 1999-11-24 CN CNA998137820A patent/CN1535314A/zh active Pending
- 1999-11-24 EP EP99962885A patent/EP1470223A4/en not_active Withdrawn
- 1999-11-24 NZ NZ511922A patent/NZ511922A/en unknown
- 1999-11-24 AU AU19234/00A patent/AU762315B2/en not_active Ceased
- 1999-11-24 WO PCT/US1999/028075 patent/WO2000032745A2/en not_active Ceased
- 1999-11-24 CA CA002352466A patent/CA2352466A1/en not_active Abandoned
- 1999-11-25 TW TW088120620A patent/TWI221481B/zh active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2003527073A (ja) | 2003-09-16 |
| AU1923400A (en) | 2000-06-19 |
| IL143415A0 (en) | 2002-04-21 |
| CN1535314A (zh) | 2004-10-06 |
| BR9916141A (pt) | 2001-12-04 |
| EP1470223A2 (en) | 2004-10-27 |
| CA2352466A1 (en) | 2000-06-08 |
| TWI221481B (en) | 2004-10-01 |
| WO2000032745A3 (en) | 2004-05-21 |
| AU762315B2 (en) | 2003-06-19 |
| RU2237716C2 (ru) | 2004-10-10 |
| WO2000032745A2 (en) | 2000-06-08 |
| EP1470223A4 (en) | 2005-04-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7344719B2 (en) | Homologous 28-kilodalton immunodominant protein genes of Ehrlichia canis and uses thereof | |
| US6403780B1 (en) | Homologous 28-kilodalton immunodominant protein genes of ehrlichia canis and uses thereof | |
| AU2001290926A1 (en) | Homologous 28-kilodalton immunodominant protein genes of ehrlichia canis and uses thereof | |
| EP1108014B1 (en) | Ehrlichia canis protein | |
| US7332171B2 (en) | Ehrlichia chaffeensis 28 kDa outer membrane protein multigene family | |
| US20040198951A1 (en) | Homologous 28-kilodalton immunodominant protein genes of Ehrlichia canis and uses thereof | |
| AU762315B2 (en) | Homologous 28-kilodalton immunodominant protein genes of ehrlichia canis and uses thereof | |
| Immunoreactive | Molecular Cloning of the Gene for | |
| MXPA01005378A (en) | Homologous 28-kilodalton immunodominant protein genes of ehrlichia canis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) | ||
| RENW | Renewal (renewal fees accepted) |